Among them, multiple tau-based immunotherapy strategies have been successfully tested in AD animal models, pointing to this as an option for treating AD (Asuni et al., 2007; Boutajangout et al., 2011; Pedersen and Sigurdsson, 2015). Here, MAPT is linked to Alzheimer disease.